Bausch+Lomb IPO Presentation Deck

Strong fundamentals supporting durable growth Organic revenue growth¹ of +9% in FY 2021 $MM Leading Growth 3,665 FY18 Market Growth? B+L REVENUE FY2018-2021 3,778 +6%1 FY19 +5% Recovery 3,412 -9%1 FY20 -6% 3,765 +9%1 FY21 +5% B+L QUARTERLY REVENUE FY2021 881 Resume Sequential Growth 934 949 Q1-21 Q2-21 Q3-21 BAUSCH + LOMB 1. Organic revenue growth (non-GAAP). See Slide 2 and Appendix for further information regarding non-GAAP measures 1,001 Q4-21 FINANCIAL PERFORMANCE Resumed sequential quarter growth in FY 2021 Substantial growth momentum in contact lens portfolio (daily SiHy, ULTRA, Biotrue®) Continued strength of key consumer health brands (PreserVision®, Artelac®) Category leader LUMIFY® extending market leadership position Market share gains and strong recovery in Vyzulta® and Minims® franchise Post Covid, broad and steady recovery with backlog of demand 2. Third party market research. Market growth comprised of Vision Care, Surgical, Ophthalmic Pharmaceuticals segments. Q3-20 LTM and Q3-21 LTM market growth reflects full calendar year 2020 and 2021E 39

View entire presentation